Patent ID: 8304407

Claim:
A method of treating cancer, comprising administering to a mammal in need thereof an effective amount of a compound of the Formula a tautomer, or a pharmaceutically acceptable salt thereof, wherein: said cancer is selected from biliary tract cancer, brain cancer, breast cancer, cervical cancer, choriocarcinoma, colon cancer, endometrial cancer, esophageal cancer, gastric cancer, intraepithelial neoplasms, leukemia, lymphoma, liver cancer, lung cancer, melanoma, neuroblastomas, oral cancer, ovarian cancer, pancreatic cancer, prostate cancer, rectal cancer, renal cancer, sarcomas, skin cancer, testicular cancer, thyroid cancer, other carcinomas and sarcomas; Y is an aryl or heteroaryl ring, wherein said aryl and heteroaryl rings are substituted with one or more groups independently selected from alkenyl, alkynyl, Br, CN, OH, NR 6 R 7 , C(═O)R 8 , NR 6 SO 2 R 7 , (C 1 -C 6 alkyl)amino, R 6 OC(═O)CH═CH—, SR 6 and SO 2 R 6 , and wherein said aryl and heteroaryl rings are optionally further substituted with one or more groups independently selected from F, Cl, CF 3 , CF 3 O—, HCF 2 O—, alkyl, heteroalkyl and ArO—; R 1 , R 3 and R 4 are independently selected from H, alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, aryl and heteroaryl, wherein said alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, aryl and heteroaryl are optionally substituted with one or more groups independently selected from alkyl, alkenyl, alkynyl, F, Cl, Br, I, CN, OR 6 , NR 6 R 7 , C(═O)R 6 , C(═O)OR 6 , OC(═O)R 6 , C(═O)NR 6 R 7 , (C 1 -C 6 alkyl)amino, CH 3 OCH 2 O—, R 6 OC(═O)CH═CH—, NR 6 SO 2 R 7 , SR 6 and SO 2 R 6 , or R 3 and R 4 together with the atom to which they are attached form a saturated or partially unsaturated carbocyclic ring, wherein said carbocyclic ring is optionally substituted with one or more groups independently selected from alkyl, alkenyl, alkynyl, F, Cl, Br, I, CN, OR 6 , NR 6 R 7 , C(═O)R 6 , C(═O)OR 6 , OC(═O)R 6 , C(═O)NR 6 R 7 , (C 1 -C 6 alkyl)amino, CH 3 OCH 2 O—, R 6 OC(═O)CH═CH—, NR 6 SO 2 R 7 , SR 6 and SO 2 R 6 ; R 2 and R 8 are independently selected from H, OR 6 , NR 6 R 7 , alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, aryl and heteroaryl, wherein said alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, aryl and heteroaryl are optionally substituted with one or more groups independently selected from alkyl, alkenyl, alkynyl, F, Cl, Br, I, CN, OR 6 , NR 6 R 7 , C(═O)R 6 , C(═O)OR 6 , OC(═O)R 6 , C(═O)NR 6 R 7 , (C 1 -C 6 alkyl)amino, CH 3 OCH 2 O—, R 6 OC(═O)CH═CH—, NR 6 SO 2 R 7 , SR 6 and SO 2 R 6 ; R 5a , R 5b , and R 5c are independently H, F, Cl, Br, I, OMe, CH 3 , CH 2 F, CHF 2 or CF 3 ; and R 6 and R 7 are independently H, alkyl, or heteroalkyl, such that said cancer is treated.